It has been a rocky few months Novo Nordisk.
Recipe data from IQVIA suggests that Novo's Obesitas -Medicijn Wegovy loses site to rival Zepbound van van Eli Lilly. The potential successor to Wegovy, Cagrisema, lacked the expectations of investors in a closely viewed phase 3 test. The shares of NOVO have fallen by more than 20% in the past year, and people feared that it would get even worse if the company released the income from the fourth quarter and its prospects from 2025 on Wednesday.
Instead, NOVO defeated the expectations of the fourth quarter and gave a turnover growth porter between 16% and 24% in line with the 20% Wall Street searched. The shares of Novo rose by more than 4%on Wednesday.
In an interview with CNBC, Novo Chief Executive Officer Lars Fruergaard Jorgensen deposited the concern that Novo was lagging behind.
“We are confident that when we enter the year and we will deliver more and more of the starter doses, we can see a nice step in our volume and serve more and more patients,” Jorgensen said. “And you can say the management we have given this year, testify to an underlying important driveway in our company. So we are quite confident in the market demand as our ability to deliver and compete in that market.”
Jonathan Raa | Nurphoto | Getty images
People who take Wegovy start with the lowest dose – or the starter dose – then work themselves up to stronger formulations so that their bodies can get used to the medicine. Sometimes NOVO has limited the amount of starter doses that it has sent because it was struggling To make enough of the medicine and wanted to ensure that people who were already using the medication could stay.
The sales guidance of Novo 2025 implies an increase of 30% of the number of patients using one of the company's GLP-1 medicines, such as Ozempic, the company said about the profit call.
The company also tried to reassure investors about the effectiveness of Cagrisema. Jorgensen said that some people had lost weight very quickly, and another group lost continuous weight, showed no signs of stopping by the time the test ended, so they may need a longer treatment.
“I have very faith in the potential of biology we have here,” he said.
People look at an earlier stage treatment-amycretine-nog closer. That experimental medicine recently showed promising results in a phase 1B/2A study.
Jorgensen said NOVO talks to the FDA about possibly going directly to a three -test phase.
